GLP-1 (glucagon-like peptide-1) medications are emerging as a transformative solution for obesity and weight management, attracting attention from healthcare providers, investors, and pharmaceutical companies. Clinical trials demonstrate significant weight reduction and improved metabolic markers, prompting wider adoption in medical practice. Analysts note that this growing market segment presents substantial economic opportunity, with projected revenues reaching several Rs. crores globally, driven by prescription demand, insurance coverage, and ancillary wellness services.